EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Narrative Review of the Strengths and Limitations of Real-World Evidence in Comparison to Randomized Clinical Trials: What Are the Opportunities in Thoracic Oncology for Real-World Evidence to Shine?

Peter M Ellis iD, Larissa Long, Courtney H Coschi, Arani Sathiyapalan

Current Oncology · 10.11.2025 · 32 (11) · 629

DOI: 10.3390/curroncol32110629 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 10.11.2025. Verfasst von Peter M Ellis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department Oncology, Division of Medical Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON L8S 4L8, Canada. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Thoracic Neoplasms, Medical Oncology. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Randomized clinical trials are considered the gold standard for the evaluation of new interventions and therapies. The results from randomized clinical trials are highly influential in treatment decision-making and decisions about the implementation of new therapeutic options within the field of oncology. This article describes a narrative review of the literature to further explore the strengths and limitations of real-world evidence in comparison to randomized clinical trials and provides a commentary on opportunities for real-world evidence in thoracic malignancies. However, randomized trials often exclude oncology patients with poorer functional status or comorbidities which are routinely considered for treatment in real-world practice. Real-world data may complement existing data from randomized clinical trials and play an important role in evaluating patterns and outcomes of care, informing everyday oncology practice. While real-world data is increasingly reported in the medical literature, strengths and limitations exist which can also limit their applicability. More work is needed to standardize methodologies for real-world studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Randomized Controlled Trials as TopicThoracic NeoplasmsMedical OncologyHumans

Stichwörter der Autor:innen

limitationsreal world evidencestrengths

Autor:innen und Institutionen

  • Department Oncology, Division of Medical Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON L8S 4L8, Canada.
  • Faculty of Health Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada.

ORCID-Profile: Peter M Ellis

Zitieren

APA

Ellis, P. M., Long, L., Coschi, C. H., & Sathiyapalan, A. (2025). A Narrative Review of the Strengths and Limitations of Real-World Evidence in Comparison to Randomized Clinical Trials: What Are the Opportunities in Thoracic Oncology for Real-World Evidence to Shine?. Current Oncology, 32(11), 629. https://doi.org/10.3390/curroncol32110629

Vancouver

Ellis PM, Long L, Coschi CH, Sathiyapalan A. A Narrative Review of the Strengths and Limitations of Real-World Evidence in Comparison to Randomized Clinical Trials: What Are the Opportunities in Thoracic Oncology for Real-World Evidence to Shine?. Current Oncology. 2025;32(11):629. doi:10.3390/curroncol32110629

BibTeX
@article{Ellis2025,
  author = {Ellis, Peter M and Long, Larissa and Coschi, Courtney H and Sathiyapalan, Arani},
  title = {A Narrative Review of the Strengths and Limitations of Real-World Evidence in Comparison to Randomized Clinical Trials: What Are the Opportunities in Thoracic Oncology for Real-World Evidence to Shine?},
  journal = {Current Oncology},
  year = {2025},
  volume = {32},
  number = {11},
  pages = {629},
  doi = {10.3390/curroncol32110629}
}
Kostenlos starten →